David A. Siegel Aptinyx Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.12 - $0.69 $23,748 - $136,551
-197,900 Reduced 92.95%
15,000 $1,000
Q4 2022

Feb 14, 2023
SELL
$0.23 - $0.34 $2,139 - $3,162
-9,300 Reduced 4.19%
212,900 $61,000
Q3 2022

Nov 14, 2022
SELL
$0.35 - $0.72 $3,919 - $8,064
-11,200 Reduced 4.8%
222,200 $82,000
Q2 2022

Aug 15, 2022
BUY
$0.38 - $2.58 $25,194 - $171,054
66,300 Added 39.68%
233,400 $130,000
Q1 2022

May 16, 2022
SELL
$2.27 - $3.62 $76,499 - $121,994
-33,700 Reduced 16.78%
167,100 $379,000
Q4 2021

Feb 14, 2022
SELL
$2.11 - $3.0 $98,537 - $140,100
-46,700 Reduced 18.87%
200,800 $536,000
Q3 2021

Nov 15, 2021
SELL
$2.21 - $2.89 $312,273 - $408,357
-141,300 Reduced 36.34%
247,500 $579,000
Q2 2021

Aug 16, 2021
SELL
$2.39 - $3.5 $561,650 - $822,500
-235,000 Reduced 37.67%
388,800 $1.1 Million
Q1 2021

May 17, 2021
BUY
$2.86 - $4.33 $429,572 - $650,366
150,200 Added 31.71%
623,800 $1.87 Million
Q4 2020

Feb 16, 2021
BUY
$2.93 - $4.3 $885,153 - $1.3 Million
302,100 Added 176.15%
473,600 $1.64 Million
Q3 2020

Nov 16, 2020
BUY
$3.05 - $4.99 $200,385 - $327,843
65,700 Added 62.1%
171,500 $580,000
Q2 2020

Aug 14, 2020
BUY
$1.99 - $4.4 $9,950 - $22,000
5,000 Added 4.96%
105,800 $441,000
Q1 2020

May 15, 2020
BUY
$1.81 - $5.03 $32,942 - $91,546
18,200 Added 22.03%
100,800 $218,000
Q4 2019

Feb 14, 2020
SELL
$2.84 - $4.25 $28,400 - $42,500
-10,000 Reduced 10.8%
82,600 $282,000
Q3 2019

Nov 14, 2019
BUY
$3.0 - $4.08 $31,500 - $42,840
10,500 Added 12.79%
92,600 $323,000
Q2 2019

Aug 14, 2019
BUY
$2.95 - $4.38 $242,195 - $359,598
82,100 New
82,100 $274,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email